RiboMed Biotechnologies, Inc. and NuvOx Pharma today jointly announced that they have entered into a collaborative agreement that will utilize RiboMed’s epigenetic biomarker test, GliomaSTRAT™, to characterize tumors from brain cancer patients and correlate response to NuvOx’s new drug, NVX-108 in the treatment of Glioblastoma multiforme (GBM).Continue reading
“The unparalleled sensitivity, accuracy, and reproducibility offered by the Abscription®-based G-CIMP test, coupled with its ability to efficiently assess multiple methylation biomarkers in FFPE patient samples, makes this the best in class option for prognostic glioma testing.”Continue reading
The Arizona BioIndustry is Moving Forward Faster in 2011
The Arizona BioIndustry Association has selected finalists and honorees for its annual awards gala to be held at the Sheraton Wild Horse Pass on Oct. 13. Awards to be presented include: 2011 Michael A. Cusanovich Educator of the Year, Fast Lane Company Awards, the Arizona Bioscience Company of the Year, the Jon W. McGarity Bioscience Leader of the Year Award, and the Arizona Bioscience Researcher of the Year Award.